PD-1 targeted Immunotherapy as first-line therapy for advanced nonsmall-cell lung cancer patients, J Thorac Dis, vol.9, pp.384-390, 2017. ,
Melanoma central nervous system metastases: current approaches, challenges, and opportunities, Pigment Cell Melanoma Res, vol.29, pp.627-669, 2016. ,
Incidence of brain metastasis at initial presentation of lung cancer, Neuro-Oncol, vol.17, pp.122-130, 2015. ,
The clinical utility of prognostic scoring systems in patients with brain metastases treated with radiosurgery, Radiother Oncol, vol.106, pp.370-374, 2013. ,
The Treatment of Melanoma Brain Metastases, Curr Oncol Rep, vol.18, p.73, 2016. ,
Dose-effect relation in stereotactic radiotherapy for brain metastases. A systematic review, Radiother Oncol, vol.98, pp.292-299, 2011. ,
Interval From Imaging to Treatment Delivery in the Radiation Surgery Age: How Long Is Too Long?, Int J Radiat Oncol, vol.93, pp.126-158, 2015. ,
RTRB-06 Time between diagnostic MRI and frame-fixed stereotactic radiosurgery planning MRI is associated with brain metastasis growth but not worse local control, Neuro-Oncol, vol.17, pp.196-196, 2015. ,
, , 2011.
, Int J Radiat Oncol Biol Phys, 2016.
Isotoxic radiosurgery planning for brain metastases, Radiother Oncol, vol.120, pp.253-260, 2016. ,
Radiosurgery for brain metastasis: impact of CTV on local control, Radiother Oncol, vol.68, p.207, 2003. ,
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial, Lancet Oncol, vol.17, issue.7, p.976, 2016. ,
, Mis en forme : Normal, Interligne : simple Mis en forme : Police :Calibri